HLX05

Other Medications

EU Experimental ES Not available 1 Clinical Trials

Description

HLX05 is an investigational medication currently being studied by Shanghai Henlius Biotech. It is not yet approved for treating colorectal cancer (CRC) or any other condition. The drug is being evaluated in clinical trials to determine its safety, how it is processed by the body (pharmacokinetics), and how the immune system responds to it (immunogenicity). Specifically, a Phase 1 trial (NCT06980454) is comparing HLX05 to Erbitux® (cetuximab) in healthy Chinese males to understand its properties. This early-stage research helps researchers understand how HLX05 works and if it could potentially be used to treat cancer in the future. It is important to remember that HLX05 is still in early development and its effectiveness and safety in CRC patients are unknown at this time.

Mechanism of Action

The specific mechanism of action for HLX05 is not yet fully defined and is being investigated in clinical trials. It is being studied in comparison to Erbitux® (cetuximab), which is a monoclonal antibody that targets the epidermal growth factor receptor (EGFR). The purpose of the current Phase 1 trial is primarily to assess the drug's properties in healthy individuals, rather than to determine its specific molecular target or mechanism in cancer cells.

Side Effects

As HLX05 is an investigational drug in early-phase trials (Phase 1) Its side effect profile is still being evaluated. The primary focus of the current trial (NCT06980454) is on safety and tolerability in healthy volunteers Not patients with cancer. Therefore Specific side effects related to treating CRC are not yet known. Information about potential side effects in patients will become available as clinical trials progress to later phases.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT06980454 Phase 1
Active, not recruiting
Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics
China

Quick Info

CategoryOther Medications
EU EMA StatusExperimental
ES Spain AccessNot available
Clinical Trials1
View Clinical Trials Back to Drug Glossary

Related Medications

Uracil
Other Medications
787 trials
Leucovorin
Other Medications
648 trials
Paclitaxel
Other Medications
54 trials
Trifluridine
Other Medications
50 trials
Cyclophosphamid
Other Medications
50 trials
Cyclophosphamide
Other Medications
49 trials

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.